Bing

SEARCH HISTORY

But Vice Chancellor Parsons determined that the suit sufficiently alleged that all the director defendants may have had material and nonpublic information about physicians' reluctance to prescribe Provenge when the executives sold their Dendreon stock.
Law 360 · 1/2/2014
Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want? The quest for perfection Stocks that look great based on one factor may prove horrible elsewhere, making ...
Daily Finance · ByDan Caplinger · 8/8/2011
We now have more data on Dendreon’s results for their prostate cancer therapy Provenge, and the numbers do, in fact, look good. This isn't a cure for refractory prostate cancer, but there seems to be a real statistical improvement in survival, with side ...
Corante · 4/30/2009
More from Bing News
Don't look now, but biotech darling Dendreon Corp. (Nasdaq: DNDN) is sucking wind. The stock had surged 119% this year on the prospect of receiving FDA approval for its novel prostate cancer treatment, Provenge. But since having that news confirmed on ...
Investment U · 7/14/2010
An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming year. Mark …
Market Watch Commentary · 3/7/2013
Just about every firm covering DNDN cut their ratings on the stock this year including BofA setting a $6 target price in July. There are the crazy price targets such as $18 by Maxim Group set in September and more reasonable $7 from Baird back in August.
Stock Masters · 10/18/2012
Shares of Dendreon Corp. surged for a second day on potential sales of its prostate cancer drug Provenge, which was cleared by the Food and Drug Administration on Thursday. Trading in company shares was suspended for a period early Thursday, but not …
Businessweek · 4/30/2010
Sep 10, 2013 (ACCESSWIRE via COMTEX) -- New York, NY - (ACCESSWIRE) - 09/10/2013 -- Equity Profile Report Initiates its Healthcare Stock Watch List adding Molex Incorporated MOLX MannKind Corp. MNKD, +10.06% Isis Pharmaceuticals, Inc. ISIS …
Market Watch · 9/10/2013
They said an investigation by the Securities and Exchange Commission into the still unexplained trading event, during which shares of Dendreon plunged more than 69 percent in 70 seconds, is ongoing. It is not clear if the SEC inquiry into the incident ...
Reuters · ByMatthew Goldstein · 3/9/2010
"Unlike defendants, who were able to sell substantial holdings of Dendreon stock before the fraud was revealed, the company's unsuspecting shareholders suffered crippling losses. As TheStreet.com put it, Gold had turned out like other Chief Executive ...
Courthouse News Service · 5/22/2013